CTLA4 and myocarditis: Anti-CTLA-4 agents were surprisingly not associated with risk of reporting pericardial toxicities (ROR: 1.36 [0.89–2.06]), in contrast to previous studies showing that anti-CTLA-4 was associated with over-reporting frequencies of myocarditis (Fan et al., 2019).